相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody
David M. Goldenberg et al.
BLOOD (2009)
Humanized Anti-CD20 Antibody, Veltuzumab, in Refractory/Recurrent Non-Hodgkin's Lymphoma: Phase I/II Results
Franck Morschhauser et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial
Anton Hagenbeek et al.
BLOOD (2008)
Acquired resistance to rituximeb is associated with chemotherapy resistance resulting from decreased Bax and Bak expression
Scott H. Olejniczak et al.
CLINICAL CANCER RESEARCH (2008)
Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels
Myron S. Czuczman et al.
CLINICAL CANCER RESEARCH (2008)
Complement activation on B lymphocytes opsonized with rituximab or ofatumumab produces substantial changes in membrane structure preceding cell lysis
Paul V. Beum et al.
JOURNAL OF IMMUNOLOGY (2008)
Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas:: a randomised controlled trial (RICOVER-60)
Michael Pfreundschuh et al.
LANCET ONCOLOGY (2008)
Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study
Bertrand Coiffier et al.
BLOOD (2008)
In vivo targeting of human neutralizing antibodies against CD55 and CD59 to lymphoma cells increases the antitumor activity of rituximab
Paolo Macor et al.
CANCER RESEARCH (2007)
Mechanisms of killing by anti-CD20 monoclonal antibodies
Martin J. Glennie et al.
MOLECULAR IMMUNOLOGY (2007)
Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphorna not appropriate for autologous stem-cell transplantation
Franck Morschhauser et al.
BLOOD (2007)
Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma:: An East German Study Group hematology and oncology study
Michael Herold et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy
Ali R. Jazirehi et al.
CANCER RESEARCH (2007)
Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia
Neil E. Kay et al.
BLOOD (2007)
The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy
Constantine S. Tam et al.
LEUKEMIA & LYMPHOMA (2007)
Aspects of chemotherapy schedules in young and elderly patients with aggressive lymphoma
Carsten Zwick et al.
CLINICAL LYMPHOMA & MYELOMA (2007)
Maintenance therapy for low-grade lymphomas: has the time come?
Guillaume Cartron et al.
CURRENT OPINION IN ONCOLOGY (2007)
Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas:: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG)
Roswitha Forstpointner et al.
BLOOD (2006)
Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial
Marinus H. J. van Oers et al.
BLOOD (2006)
Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab
Julie A. Bowles et al.
BLOOD (2006)
Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity
Tom van Meerten et al.
CLINICAL CANCER RESEARCH (2006)
The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20
Jessica L. Teeling et al.
JOURNAL OF IMMUNOLOGY (2006)
Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia
N Lamanna et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma
Constantine S. Tam et al.
CANCER (2006)
Rituximab - A review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia
Risto S. Cvetkovic et al.
DRUGS (2006)
Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone:: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group
W Hiddemann et al.
BLOOD (2005)
Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia
W Wierda et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia
MJ Keating et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Maximizing therapeutic benefit of rituximab: Maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma - A randomized phase II trial of the minnie pearl cancer research network
JD Hainsworth et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma
R Marcus et al.
BLOOD (2005)
Lymphoma: Diagnosis, staging, natural history, and treatment strategies
PL Zinzani
SEMINARS IN ONCOLOGY (2005)
Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma
R Stein et al.
CLINICAL CANCER RESEARCH (2004)
Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents
MS Cragg et al.
BLOOD (2004)
Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas
JL Teeling et al.
BLOOD (2004)
Follicular lymphoma international prognostic index
P Solal-Céligny et al.
BLOOD (2004)
Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly X 4 schedule
M Ghielmini et al.
BLOOD (2004)
A pilot trial of rituximab and alemtuzumab combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL)
C Nabhan et al.
LEUKEMIA & LYMPHOMA (2004)
Role of fludarabine as monotherapy in the treatment of chronic lymphocytic leukemia
M Leporrier
HEMATOLOGY JOURNAL (2004)
Complement activation determines the therapeutic activity of rituximab in vivo
N Di Gaetano et al.
JOURNAL OF IMMUNOLOGY (2003)
Selective internalization of monoclonal antibodies by B-cell chronic lymphocytic leukaemia cells
T Sieber et al.
BRITISH JOURNAL OF HAEMATOLOGY (2003)
Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies
S Faderl et al.
BLOOD (2003)
In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas
O Manches et al.
BLOOD (2003)
Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts
MS Cragg et al.
BLOOD (2003)
Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712)
JC Byrd et al.
BLOOD (2003)
Anti-CD20-based therapy of B cell lymphoma: state of the art
C Kosmas et al.
LEUKEMIA (2002)
Standard-dose anti-CD20 antibody rituximab has efficacy in chronic lymphocytic leukaemia:: results from a Nordic multicentre study
M Itälä et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2002)
Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene
G Cartron et al.
BLOOD (2002)
Rituximab therapy of patients with B-cell chronic lymphocytic leukemia
D Huhn et al.
BLOOD (2001)
Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies
SP Treon et al.
JOURNAL OF IMMUNOTHERAPY (2001)
Rituximab dose-escalation trial in chronic lymphocytic leukemia
SM O'Brien et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
分享论文
